牛牛AI助手已提取核心信息
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
On December 31, 2023, a filing was made with the United States Securities and Exchange Commission (SEC) by Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz, indicating that they do not hold any shares of Virpax Pharmaceuticals, Inc. The Schedule 13G/A amendment filing, which is a requirement for certain levels of ownership in a company, shows that these entities and individuals have ceased to be the beneficial owners of more than five percent of Virpax Pharmaceuticals' common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934. Sabby Management, LLC, based in Delaware, and Hal Mintz, a U.S. citizen, are associated with the Cayman Islands-based Sabby Volatility Warrant Master Fund, Ltd. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing the control of Virpax Pharmaceuticals and were not held in connection with any transaction having that purpose or effect. The joint filing agreement was dated January 2, 2024.
2023年12月31日，Sabby Volatility Warrant, Master Fund, LLC、Sabby Management, LLC和Hal Mintz向美国证券交易委员会（SEC）提交了一份文件，表明这些实体和个人已不再是更多公司的受益所有人。附表13G/A修正案文件显示，这些实体和个人已不再是更多公司的受益所有者超过Virpax Pharmaceuticals普通股的百分之五。该文件是根据1934年《证券交易法》第13d-1（c）条提交的。总部位于特拉华州的Sabby Management, LLC和美国公民哈尔·明兹与总部位于开曼群岛的Sabby Volitality...展开全部
2023年12月31日，Sabby Volatility Warrant, Master Fund, LLC、Sabby Management, LLC和Hal Mintz向美国证券交易委员会（SEC）提交了一份文件，表明这些实体和个人已不再是更多公司的受益所有人。附表13G/A修正案文件显示，这些实体和个人已不再是更多公司的受益所有者超过Virpax Pharmaceuticals普通股的百分之五。该文件是根据1934年《证券交易法》第13d-1（c）条提交的。总部位于特拉华州的Sabby Management, LLC和美国公民哈尔·明兹与总部位于开曼群岛的Sabby Volitality Warrance Master Fund有限公司有关联。该文件包括一份证明，收购这些证券不是为了改变或影响Virpax Pharmicals的控制权，也不是为了改变或影响Virpax Pharmicals的控制权而持有，也不是与任何具有该目的或效果的交易有关的。联合申报协议的日期为2024年1月2日。
有用
没用